Vasculitis & polymyalgia rheumatica

Longitudinal orientation of temporal artery biopsy for the diagnosis of giant cell arteritis: A cross-sectional study

Semin Arthritis RheumPublished Cross-sectional study

Main finding · TAB positivityResult — go to the resultOdds ratio 2.93 95% CI 1.07–8.04

Authors' conclusion

This is the first study to suggest that the use of a longitudinal section for TAB results in a higher diagnostic yield than the transverse orientation.

Study context

Population
Patients with giant cell arteritis (GCA) meeting the 1990 ACR classification criteria, from a multicentre prospective cohort
Participants
69 vs 337
Exposure
Longitudinal vs transverse temporal artery biopsy (TAB) section orientation
  • Longitudinaln = 69
  • Transversen = 337reference
Outcome
TAB positivity rate
Methodological detailsmulticentre, prospective cohort, blinded independent pathologist review, adjusted for confounding factors, Two independent pathologists blind to the relevant clinical data reviewed the TAB specimens
  • Multicentre
  • Prospective cohort
  • Blinded independent pathologist review
  • Adjusted for confounding factors
  • Two independent pathologists blind to the relevant clinical data reviewed the TAB specimens

Main finding

TAB positivity

Odds ratio

2.93

95% CI 1.07–8.04

Longitudinalvs Transverse
OR 2.93 (95% CI 1.07–8.04)

As reported in the abstract

Positive TAB results with longitudinal section
15.0% more

Observational data: associations, not effects.

Further findings

Histological features

Giant cells, inflammatory cells, nerve inflammation and disruption of the internal elastic lamina all more frequent on longitudinal than transverse sections

Original publication

Longitudinal orientation of temporal artery biopsy for the diagnosis of giant cell arteritis: A cross-sectional study. Semin Arthritis Rheum. Published 8 April 2026. doi:10.1016/j.semarthrit.2026.152977

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.